The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
For those of you in development and/or implementation of automated production systems, or considering revising your data integrity strategy, following good automated manufacturing practices (GAMP®) guidelines may be the best method to achieve your desired goals. The GAMP guidelines have undergone a significant review by the international pharmaceutical industry and regulatory subject matter experts, and the processes have been successfully deployed at many pharmaceutical companies large and small. As we all know, computer systems are at the crux of every decision made within a life sciences company, and they control many processes in manufacturing and laboratories. With the increase of data integrity issues, regulatory focus on computerized systems has amplified. Now more than ever, practical industry guidance is critical when establishing or re-evaluating strategies to achieve compliant computerized systems. Companies that develop a data integrity program using the GAMP guidelines have a better chance of ensuring their systems function in the way they are intended—safeguarding product quality and patient safety as well as meeting regulatory needs. While it is preferable and easier to apply GAMP principles from cradle to grave, companies that are considering introducing these practices can still benefit by applying them to support existing systems as well. Before developing your data integrity strategy, I recommend you ensure that all your contributors have a practical understanding of the tools and techniques needed to establish compliant computerized systems. As an instructor of the ISPE GAMP® Data Integrity 21 CFR Part 11 training course, I can tell you that there are many advantages to completing such training including:
As data integrity is increasingly the focus of regulatory agencies, it is important that your team understands the challenges and utilizes powerful resources like the GAMP guidelines to ensure compliance.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...